港股異動 | 莊士機構國際(0367.HK)高開逾14% 擬不超16.51億港元出售Flying Dragon及逸公司股份
格隆匯12月21日丨莊士機構國際(0367.HK)高開逾14%,報0.97港元創近五個月新高,總市值16億港元。莊士機構國際公吿,於2021年12月20日,公司及Fanus(公司全資附屬公司)作為該等賣方與買方VIA IV (BVI) Holdco 7 Ltd訂立買賣協議,賣方同意出售及買方有條件同意購買及承讓銷售股份(即Flying Dragon股份及逸公司股份)及相關貸款(即Flying Dragon貸款及逸公司貸款)。銷售股份及銷售貸款的代價估計將不高於16.51億港元。該物業座落於紅磡的中心地段,毗鄰三個港鐵站。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.